UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 7, 2020

NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware	**001-39398**	**27-0838048**
(State or Other Jurisdiction of Incorporation or Organization)	**(Commission File Number)**	**(IRS Employer Identification No.)**

1700 Owens Street, Suite 205 **San Francisco, California** **(Address of Principal Executive Offices)**	**94158** **(Zip Code)**

(415) 660-5320
(Registrant's Telephone Number, Including Area Code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	**NRIX**	**Nasdaq Global Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 7, 2020, Nurix Therapeutics, Inc. (the "Company") presented at the 62nd American Society of Hematology Annual Meeting and Exposition (the "Presentation"). A copy of the Presentation is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

The information furnished with this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Forward Looking Statements

This Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements and information relating to Nurix Therapeutics, Inc. (the "Company," "we," "us" or "our"). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical results and other future conditions. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates; the potential advantages of NX-2127; the extent animal model data predicts human efficacy; and the success and timing of our development and commercialization of our product candidates. In addition, when or if used in this presentation, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from those expressed or implied in our forward-looking statements due to a variety of factors, including risks and uncertainties related to our ability to advance our product candidates; obtain regulatory approval of and ultimately commercialize our product candidates; the timing and results of preclinical and clinical trials; our ability to fund development activities and achieve development goals; the impact of the COVID-19 pandemic on our business; our ability to protect intellectual property; and other risks and uncertainties described under the heading "Risk Factors" in our final prospectus pursuant to Rule 424(b)(4) filed with the Securities and Exchange Commission (the "SEC") on July 24, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended August 31, 2020, as well as other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Exhibit Title or Description
99.1	Presentation dated December 7, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

NURIX THERAPEUTICS, INC.

Date: December 7, 2020

By: /s/ Christine Ring
Christine Ring, Ph.D., J.D.
General Counsel

Exhibit 99

NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Presenter: Daniel Robbins, Ph. D.

drobbins@nurixtx.com

Disclosures

All authors of this presentation are current or former employees and shareholders of Nurix Therapeutics.

NX-2127 has a dual degradation mechanism of action for two clinically validated targets

- BTK is a tyrosine kinase involved in B cell development, differentiation and signaling
- BTK inhibitors are approved for treatment of B cell malignancies
- Mutations to BTK have conferred resistance to approved agents indicating an area of unmet medical need
- IMiD therapies have shown efficacy in some aggressive B-cell malignancies
- The dual action of BTK degradation and IMiD activity may provide a unique treatment strategy for relapsed/refractory B-cell malignancies



(A) NX-2127 is a novel, hetero-bifunctional, orally administered, Chimeric Targeting Molecule (CTM) that induces the degradation of Bruton's Tyrosine Kinase (BTK) in cells through recruitment of cereblon (CRBN), a component of the CRL4-CRBN ubiquitin ligase complex

(B) The engagement of NX-2127 also catalyzes neosubstrate degradation of Aiolos (IKZF3) and Ikaros (IKZF1), two transcription factors regulating T-cell function

NX-2127 catalyzes BTK degradation and anti-proliferative activity in cancer cell lines

A



B



C



(A) NX-2127 catalyzes potent degradation of BTK in DLBCL cell lines (TMD8), including cells with the ibrutinib-resistance mutation BTK^{C481S}

(B) NX-2127 catalyzes BTK degradation in Rec-1 and Mino mantle cell lymphoma cell lines

(C) NX-2127 potently blocks cell proliferation of BTK^{C481S} TMD8 cells relative to ibrutinib

DC_{50} = half maximal degradation concentration
HTRF = Homogeneous Time Resolved Fluorescence

NX-2127 has minimal *in vitro* effects on platelet aggregation



- NX-2127 does not show significant inhibition of platelet aggregation in an *in vitro* platelet aggregation assay

nurix

NX-2127 catalyzes Aiolos degradation and IL-2 production similar to IMiD drugs

IMiD Activity: Aiolos Degradation in Naïve Human T Cells



- NX-2127 degrades Aiolos with similar potency to that of pomalidomide and lenalidomide

IMiD Activity: T Cell Activation and IL-2 Secretion



- NX-2127 exhibits IMiD-like activity by activation and IL-2 production following CD3/CD28 stimulation

Oral Administration of NX-2127 Demonstrates Cancer Growth Inhibition in Mouse Xenograft Tumor Model

Tumor Growth Inhibition in Xenograft Model of Wild Type Lymphoma



- NX-2127 demonstrates comparable tumor growth inhibition to ibrutinib in a xenograft mouse model containing tumors with a wild type BTK

Tumor Growth Inhibition in Xenograft Model of Mutant Ibrutinib-Resistant Lymphoma



- NX-2127 shows more potent tumor growth inhibition compared to ibrutinib in a xenograft mouse model containing tumors with the most common human resistance mutation (C481S) in BTK target protein

Oral Dosing of NX-2127 Degrades BTK in Cynomolgus Monkey



- NX-2127 induces significant degradation of BTK in 4 hours and more than 90% degradation through 24 hours post dose
- Once daily, oral dosing of NX-2127 maintains suppression of BTK protein levels throughout the 19-day duration of the study (NX-2127 PK $t_{1/2}$ = 5.4 h)

Summary and Conclusions

- NX-2127 catalyzes potent BTK degradation *in vitro* and results in anti-proliferative effects in human lymphoma cell lines
- The IMiD activity of NX-2127 is similar to that of IMiD drugs pomalidomide and lenalidomide and results in T-cell activation
- NX-2127 demonstrates potent BTK degradation *in vivo* upon oral dosing in cynomolgus monkey and displays anti-tumor effects in both wild-type and C481S mutant mouse xenograft tumor models
- NX-2127 combines BTK degradation with IMiD activity to provide an attractive therapeutic strategy in the setting of resistance mutations and an expanded set of B-cell malignancies

Acknowledgements

Biology & Lead Discovery
Jordan Ye
Mark Noviski
Austin Tenn-McClellan
Szerenke Kiss von Soly
Jennifa Gosling
Karl Doerner
Stephanie Yung
Kathleen Boyle
Diana Muñoz
Steve Basham

Preclinical Pharmacology
May Tan
Anna Kolobova
Luz Perez
Jennifer Tung
Ryan Rountree
Jennie Stokes
Sasha Borodovsky

Chemistry
Daisuke Kato
Zef Konst
Jose Leighton
Oliver McConnell
Joel McIntosh
Ge Peng
Josh Taygerly
Jeffrey Wu
Jeff Mihalic
Christoph Zapf

Development
Timothy Ingallinera
Janine Powers
Jenny McKinnell
Dane Karr

Drug Discovery Technologies
Eileen Ambing
Andrew Sawayama
Naimee Mehta
Herman Yuen
Paul Novick
Jose Santos
Dahlia Weiss
Mario Cardozo
Matt Clifton
Stefan Gajewski

Collaborators
NIH NHLBI
Adrian Wiestner
Sarah Herman
Hailey Harris
Deyi Zhang
Tokyo Medical and Dental University (TMD8 cells)

Project Leadership & Project Management
Aileen Kelly
Dan Robbins
Elsa Tretter

Nurix Leadership
Arthur Sands
Pierre Beaurang
Robert Brown
Hans Van Houte
Cristiana Guiducci
Gwenn Hansen
Howard Simon
Jason Kantor
Chris Ring
Jean Chang

nurix